Applied Genetic Technologies Corporation (AGTC)

CVR Agreement

Milestone 1” means (a) the sale, license, transfer, spin-off of, or the occurrence of any other monetizing event, whether in a single or multiple transactions, involving, all or any part of the Non-RPGR Assets, (b) the sale or transfer of the Bionic Sight Equity and/or (c) the sale, lease or transfer of the Manufacturing Assets, in each case, that closes on or prior to the Milestone 1 Deadline Date and other than, in each case, any such transaction involving solely a Parent Affiliate and in which the Company, the Purchaser, Parent or any Parent Affiliate receives aggregate Gross Proceeds in excess of five million dollars ($5,000,000).

“Milestone 1 Amount” means, with respect to the achievement of Milestone 1, an amount per CVR equal to the quotient of: (A) the amount by which the sum of (i) sixty percent (60%) of the Gross Proceeds attributable to the Non-RPGR Assets and/or (ii) one hundred percent (100%) of the Gross Proceeds attributable to the Bionic Sight Assets and/or (iii) one hundred percent (100%) of the Gross Proceeds attributable to the Manufacturing Assets (reduced as set out in the final sentence of the definition of Gross Proceeds above), collectively, exceeds five million dollars ($5,000,000), divided by (B) the total number of CVRs outstanding as of the date of achievement of Milestone 1; provided, however, that, in no event shall the aggregate amount payable to all Holders of CVRs in connection with the achievement of Milestone 1 exceed twelve million five hundred thousand dollars ($12,500,000) in the aggregate (the “Maximum Milestone 1 Amount”).

“Milestone 1 Deadline Date” means the date that is eighteen (18) months after the Closing Date of the Merger.

“Milestone 2” means FDA approval of a BLA for AGTC-501 to treat patients with XLRP caused by mutations in the RPGR gene, as evidenced by the written notice of such approval by the FDA; provided, that, such approval (a) must be consistent with the patient population, at a minimum, as established by the inclusion/exclusion criteria of patients studied in the pivotal clinical trial, (b) may be subject to conditions of use, contraindications, or otherwise limited, and (c) may contain a commitment to conduct a post-approval study or clinical trial (the “Marketing Approval”).

“Milestone 2 Amount” means, with respect to the achievement of Milestone 2, an amount per CVR equal to twelve million five hundred thousand dollars ($12,500,000) divided by the total number of CVRs outstanding as of the date of achievement of Milestone 2.

“Milestone 3” means, as of the date of Marketing Approval, that no other AAV gene therapy product expressing the RPGR protein (including any derivative or shortened version of the RPGR protein) has received a marketing approval from the FDA.

“Milestone 3 Amount” means, with respect to the achievement of Milestone 3, an amount per CVR equal to twelve million five hundred thousand dollars ($12,500,000) divided by the total number of then-outstanding CVRs.

“Milestone 4” means the first date on which Net Sales in any Calendar Year is equal to or exceeds one hundred million dollars ($100,000,000).

“Milestone 4 Amount” means, with respect to the achievement of Milestone 4, an amount per CVR equal to twelve million five hundred thousand dollars ($12,500,000) divided by the total number of CVRs outstanding as of the date of achievement of Milestone 4.

https://www.sec.gov/Archives/edgar/data/1273636/000119312522267229/d371149dex101.htm

AGTC closed at $0.3936 on 11/30/22.

Paid $0.39268 per share or $0.05268 net.

Syncona Limited Portfolio Company Successfully Completes Tender Offer and Acquisition of Applied Genetic Technologies Corporation (12/01/22)

Applied Genetic Technologies Corporation (“AGTC” or the “Company”) (Nasdaq: AGTC), announced today the successful completion of the previously announced tender offer (the “Offer”) to purchase all of the issued and outstanding shares of common stock of AGTC by a portfolio company of Syncona Limited (LON: SYNC) (“Syncona”). The Offer, as extended, expired at 5:00 p.m., Eastern Time, on November 30, 2022, and the acquisition was completed through a merger under Section 251(h) of the General Corporation Law of the State of Delaware. Pursuant to the terms of the definitive merger agreement, AGTC stockholders are entitled to receive $0.34 per share in cash at closing, plus up to an additional $0.73 per share payable pursuant to contingent value rights (CVRs) upon the achievement of specified milestones.

As a result of the merger, AGTC has become an indirect, wholly owned subsidiary of Syncona Limited. In the merger, each share of AGTC (other than those shares held by Syncona or AGTC or any of their respective subsidiaries or shares held by any stockholder who properly demand appraisal under Delaware law) was cancelled and converted into the right to receive the same consideration, without interest, less any applicable withholding taxes, that was paid in the Offer. As of November 30, 2022, the common stock of AGTC will no longer be listed for trading on the Nasdaq Global Stock Market.

About AGTC

AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. AGTC is designing and constructing critical gene therapy elements and bringing them together to develop customized therapies with the potential to address unmet patient needs. AGTC’s most advanced clinical programs in XLRP and ACHM CNGB3 leverage its technology platform to potentially improve vision for patients with inherited retinal diseases. Its preclinical programs build on the AGTC’s AAV manufacturing technology and scientific expertise. AGTC is advancing multiple pipeline candidates to address substantial unmet clinical needs in optogenetics, otology and CNS disorders, and has entered into strategic collaborations with companies including Bionic Sight, Inc., an innovator in the emerging field of optogenetics and retinal coding, and Otonomy, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology.

About Syncona Limited

Syncona's purpose is to invest to extend and enhance human life. We do this by founding and building companies to deliver transformational treatments to patients in areas of high unmet need.

Our strategy is to found, build and fund companies around exceptional science to create a diversified portfolio of 15-20 globally leading healthcare businesses for the benefit of all our stakeholders. We focus on developing treatments for patients by working in close partnership with world-class academic founders and management teams. Our balance sheet underpins our strategy enabling us to take a long-term view as we look to improve the lives of patients with no or poor treatment options, build sustainable life science companies and deliver strong risk-adjusted returns to shareholders.

https://www.globenewswire.com/news-release/2022/12/01/2565756/30580/en/Syncona-Limited-Portfolio-Company-Successfully-Completes-Tender-Offer-and-Acquisition-of-Applied-Genetic-Technologies-Corporation.html

Most likely alternative for AGTC is filing for bankruptcy.
On October 20, 2022, the Company engaged a nationally known restructuring financial expert in case the Company was unable to consummate the proposed transaction with Syncona and a bankruptcy filing became necessary.
https://www.sec.gov/Archives/edgar/data/1273636/000119312522269728/d384239dsc14d9.htm

Syncona Limited Portfolio Company Extends Tender Offer to Acquire Applied Genetic Technologies Corporation (11/29/22)

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (“AGTC” or the “Company”) (Nasdaq: AGTC), announced today that a portfolio company of Syncona Limited (LON: SYNC) (“Syncona”) has extended the expiration of its previously announced tender offer to purchase all of the issued and outstanding shares of AGTC common stock for $0.34 per share in cash at closing, plus up to an additional $0.73 per share payable pursuant to contingent value rights (CVRs) upon the achievement of specified milestones.

The tender offer has been extended until 5:00 p.m., Eastern Time, on November 30, 2022. The tender offer was previously scheduled to expire at 5:00 p.m., Eastern Time, on November 28, 2022. All other terms and conditions of the tender offer remain unchanged during the extension period. The tender offer is being extended in order to allow additional time for shareholders to tender their shares and for shares tendered by notice of guaranteed delivery to be received.

Computershare Trust Company, N.A., the depositary for the offer, has advised that as of 5:00 p.m., Eastern Time, on November 28, 2022, 30,947,430 shares of AGTC, representing approximately 45.1% of the issued and outstanding shares of common stock and restricted stock units, have been validly tendered and not validly withdrawn pursuant to the Offer. Additionally, the depositary has advised that an additional 4,627,261 shares had been tendered by notice of guaranteed delivery, representing approximately 6.7% of AGTC’s issued and outstanding shares of common stock and restricted stock units. Holders that have previously tendered their shares do not need to re-tender their shares or take any other action in response to this extension.

Complete terms and conditions of the tender offer are set forth in the Offer to Purchase, Letter of Transmittal and other related materials, which have been filed by Syncona Limited with the Securities and Exchange Commission (“SEC”) and sent to shareholders. In addition, AGTC filed a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC that includes, among other things, the recommendation of AGTC’s board of directors that AGTC stockholders tender all their shares in the tender offer.

If you did not receive or cannot locate the materials referenced above, please contact Georgeson LLC, the information agent for the transaction, at (800) 279-6913. You may also review the materials at our website at https://ir.agtc.com/financial-information/sec-filings.

About AGTC

AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. AGTC is designing and constructing critical gene therapy elements and bringing them together to develop customized therapies with the potential to address unmet patient needs. AGTC’s most advanced clinical programs in XLRP and ACHM CNGB3 leverage its technology platform to potentially improve vision for patients with inherited retinal diseases. Its preclinical programs build on the AGTC’s AAV manufacturing technology and scientific expertise. AGTC is advancing multiple pipeline candidates to address substantial unmet clinical needs in optogenetics, otology and CNS disorders, and has entered into strategic collaborations with companies including Bionic Sight, Inc., an innovator in the emerging field of optogenetics and retinal coding, and Otonomy, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology.

About Syncona Limited

Syncona's purpose is to invest to extend and enhance human life. We do this by founding and building companies to deliver transformational treatments to patients in areas of high unmet need.

Our strategy is to found, build and fund companies around exceptional science to create a diversified portfolio of 15-20 globally leading healthcare businesses for the benefit of all our stakeholders. We focus on developing treatments for patients by working in close partnership with world-class academic founders and management teams. Our balance sheet underpins our strategy enabling us to take a long-term view as we look to improve the lives of patients with no or poor treatment options, build sustainable life science companies and deliver strong risk-adjusted returns to shareholders.

Additional Information and Where to Find It

A tender offer statement on Schedule TO, including an offer to purchase, a letter of transmittal and related documents, have been filed with the SEC by subsidiaries of Syncona Limited, and a Solicitation / Recommendation Statement on Schedule 14D-9 has been filed with the SEC by the Company. The offer to purchase shares of Company common stock is being made pursuant to the offer to purchase, the letter of transmittal and related documents filed as a part of the Schedule TO. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ BOTH THE TENDER OFFER STATEMENT AND THE SOLICITATION / RECOMMENDATION STATEMENT REGARDING THE OFFER, AS THEY MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME, BECAUSE THEY CONTAIN IMPORTANT INFORMATION THAT INVESTORS AND SECURITY HOLDERS SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR COMMON STOCK, INCLUDING THE TERMS AND CONDITIONS OF THE TENDER OFFER. Investors and security holders may obtain a free copy of these statements and other documents filed with the SEC at the website maintained by the SEC at www.sec.gov or by directing such requests to Georgeson LLC, Information Agent for the Offer, toll-free at (800) 279-6913. Investors may also obtain, at no charge, the documents filed or furnished to the SEC by the Company under the “Investors” section of the Company’s website at www.AGTC.com.

https://www.globenewswire.com/news-release/2022/11/29/2563939/30580/en/Syncona-Limited-Portfolio-Company-Extends-Tender-Offer-to-Acquire-Applied-Genetic-Technologies-Corporation.html

Wainright gave them a $24 target yesterday.
https://ih.advfn.com/stock-market/NASDAQ/applied-genetic-technolo-AGTC/stock-news/88676608/h-c-wainwright-thinks-applied-genetic-technologie

AGTC Clinical Trial Investigators to Present Data from Ongoing XLRP and Achromatopsia Phase 1/2 Trials at the Fourteenth International Symposium on Retinal Degeneration
8:00 am ET September 28, 2021 (Globe Newswire) Print

Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases, today announced a presentation of the Company's ongoing clinical trials in achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP) at the Fourteenth International Symposium on Retinal Degeneration (RD2021).

Rachel Huckfeldt, MD, PhD, Assistant Professor of Ophthalmology at Harvard Medical School will present Twelve-month Findings from Two Phase 1/2 Clinical Trials of Subretinal Gene Therapy for Achromatopsia in adults and low-dose pediatrics on September 29, 2021, at 9:35 AM ET.

Paul Yang, MD, PhD, Assistant Professor of Ophthalmology at the Casey Eye Institute, Oregon Health & Science University in Portland, will present Twelve-Month Analysis of Macular Structure using Optical Coherence Tomography (OCT) from a Phase 1/2 Clinical Study of Subretinal Gene Therapy Drug AGTC-501 for X-Linked Retinitis Pigmentosa, on September 29, 2021, at 10:35 AM ET.

"We look forward to our investigators having the opportunity to share analysis of these results with members of the eye health community," said Sue Washer, President and CEO of AGTC. "We believe the data provide important validation for the broad application of our AAV technology platform, including the best-in-class potential for our XLRP therapy candidate and further clinical investigation of our therapy to treat ACHM."

"ACHM is an inherited condition caused by mutations in one of several genes, including the CNGB3 or CNGA3 genes, resulting in nonfunctioning "cone" photoreceptors responsible for color vision, and is associated with poor visual acuity, extreme light sensitivity leading to daytime blindness, and partial or complete loss of color discrimination," said Dr. Huckfeldt. "These results are very encouraging, and I look forward to sharing them with my fellow retinal specialists."

"Patients with XLRP experience damage to photoreceptors in the retina (both rods and cones) leading to declining vision in dim light conditions and progressive peripheral vision loss that can eventually result in legal blindness," said Dr. Yang. "The sustained durability of improved visual function over 12 months is compelling evidence of biological activity for this XLRP gene therapy."

AGTC plans to advance its ACHM program to the next stage of clinical development and is moving forward on an End-of-Phase 2 (EOP2) briefing packet to submit to the U.S. Food and Drug Administration, developing assays for pivotal ready testing, and planning production of clinical trial material. Along with the 12-month results in XLRP and other key XLRP data previously released by the company, AGTC is currently executing the Skyline and Vista Phase 2/3 trials that will expand safety and efficacy analyses, including microperimetry and luminance mobility maze outcomes.

Learn more and register here for the virtual/digital event to attend these important presentations: https://bit.ly/3z9uHre.

About AGTC

AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies that address real patient needs. AGTC's most advanced clinical programs leverage its best-in-class technology platform to potentially improve vision for patients with an inherited retinal disease. AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHMB3 and ACHMA3). Its preclinical programs build on the Company's industry leading AAV manufacturing technology and scientific expertise. AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders. In recent years AGTC has entered into strategic partnerships with companies including Otonomy, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, and Bionic Sight, LLC, an innovator in the emerging field of optogenetics and retinal coding.

Forward-Looking Statements

This release contains forward-looking statements that reflect AGTC's plans, estimates, assumptions and beliefs, including statements about the potential of the Company's late-stage development programs in X-Linked Retinitis Pigmentosa (XLRP) and Achromatopsia (ACHM). Forward-looking statements include information concerning possible or assumed future results of operations, financial guidance, business strategies and operations, preclinical and clinical product development and regulatory progress, potential growth opportunities, potential market opportunities, the effects of competition and the impact of the COVID-19 pandemic, including the impact on its ability to obtain the raw materials necessary to conduct its clinical trials. Forward-looking statements include all statements that are not historical facts and can be identified by terms such as "anticipates," "believes," "could," "seeks," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," "would" or similar expressions and the negatives of those terms. Actual results could differ materially from those discussed in the forward-looking statements, due to a number of important factors. Risks and uncertainties that may cause actual results to differ materially include, among others: gene therapy is still novel with only a few approved treatments so far; AGTC cannot predict when or if it will obtain regulatory approval to commercialize a product candidate or receive reasonable reimbursement; uncertainty inherent in clinical trials and the regulatory review process; risks and uncertainties associated with drug development and commercialization; the direct and indirect impacts of the ongoing COVID-19 pandemic on our business, results of operations, and financial condition; factors that could cause actual results to differ materially from those described in the forward-looking statements are set forth under the heading "Risk Factors" in our most recent annual report on Form 10-K and subsequent periodic reports filed with theâ?¯SEC. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, forward-looking statements represent management's plans, estimates, assumptions and beliefs only as of the date of this release. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

PR Contact:

Bryan Blatstein

Spectrum Science Communications

T: (212) 468-5379 or (917) 714-2609

bblatstein@spectrumscience.com

Corporate Contact:

Stephen Potter

Chief Business Officer

Applied Genetic Technologies Corporation

T: (617) 413-2754

spotter@agtc.com

https://ml.globenewswire.com/media/542616ce-01ae-469d-b4ff-5285f7e0584e/small/applied-genetic-technologies-logo.jpg

Important readouts today or tomorrow

AGTC hosting conference call Thursday 8AM to discuss results


AGTC to Host Conference Call on June 24 at 8:00 AM ET to Discuss Achromatopsia 12-Month Data in its Ongoing CNGB3 and CNGA3 Phase 1/2 Clinical Trials
4:03 pm ET June 23, 2021 (Globe Newswire) Print

Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare retinal diseases, today announced that it plans to release 12-month data for adult patients and low dose pediatric patients in its Phase 1/2 clinical Achromatopsia (ACHM) trials on Thursday, June 24, 2021. AGTC management will host a conference call and webcast with accompanying slides beginning at 8:00 AM Eastern Time on the same date to review the ACHM CNGB3 and CNGA3 data and provide an update on the trials.

The live webcast will be available in the Events and Presentations section of the Investor Relations page at http://ir.agtc.com/events-and-presentations. To access the call, dial 877-407-6184 (US) or 201-389-0877 (outside of the US). The archived webcast and slide presentation will be available in the Events and Presentations section of the Company's website.

About AGTC

AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies that address real patient needs. AGTC's most advanced clinical programs leverage its best-in-class technology platform to potentially improve vision for patients with an inherited retinal disease. AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM CNGB3 and ACHM CNGA3). Its preclinical programs build on the Company's industry leading AAV manufacturing technology and scientific expertise. AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders. In recent years AGTC has entered into strategic partnerships with companies including Otonomy, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, and Bionic Sight, LLC, an innovator in the emerging field of optogenetics and retinal coding.

IR/PR CONTACTS:

David Carey (IR) or Glenn Silver (PR)

Lazar FINN Partners

T: 212-867-1768 or 646-871-8485

david.carey@finnpartners.com or glenn.silver@finnpartners.com

Corporate Contact:

Stephen Potter

Chief Business Officer

Applied Genetic Technologies Corporation

T: 617-413-2754

spotter@agtc.com

https://ml.globenewswire.com/media/542616ce-01ae-469d-b4ff-5285f7e0584e/small/applied-genetic-technologies-logo.jpg

https://ml.globenewswire.com/media/542616ce-01ae-469d-b4ff-5285f7e0584e/small/applied-genetic-technologies-logo.jpg

Agreed, relatively new firm it seems: About BTIG

BTIG is a global financial services firm specializing in institutional trading, investment banking, research and related brokerage services. With an extensive global footprint and more than 650 employees, BTIG, LLC and its affiliates operate out of 19 cities throughout the U.S., and in Europe, Asia and Australia.

Never heard of them....but looks like a credible firm...

https://www.btig.com/

https://www.btig.com/news/btig-continues-expansion-of-financials-research-coverage-with-industry-recognized-mortgage-and-specialty-finance-analyst-timothy-hayes/#:~:text=BTIG%20is%20a%20global%20financial,in%20Europe%2C%20Asia%20and%20Australia.

Hopefully AGTC is on the high road for a while...

New buy rating and $11 target from BTIG

Anything good happening here?...Stock price looks like it may be a good buy...

(Nasdaq: AGTC). Mutations in the GJB2 gene are the most common cause of congenital hearing loss and typically result in moderate to severe hearing impairment.

"We are excited to present these preclinical results for OTO-825 that build on our previous presentations demonstrating gene expression in support cells of the cochlear, which are the target cells for GJB2 gene therapy, using novel AAV vectors identified through our collaboration with AGTC,” said Alan C. Foster, Ph.D., chief scientific officer of Otonomy. “Based on these encouraging results that demonstrate hearing recovery and improved cochlear morphology following OTO-825 administration, the companies have initiated IND-enabling activities and look forward to providing additional details of the program in the next several months.”

https://finance.yahoo.com/news/otonomy-agtc-present-preclinical-proof-113000630.html

$AGTC to present at upcoming investor conference. $14.00 price target by Stifel

$AGTC initiated as a buy @14.00 by Stifel Nicolaus. Chart says moving up as well.

YEAH!!! ARE MOVING TODAYL OR WHAT?????
Robinhood is setting this at 100% to buy

[img][/img]

Nice Cap raise, orderly and quick!! Now we move much higher with $75mm in the bank

$AGTC #AGTC https://www.globenewswire.com/news-release/2021/01/27/2165357/0/en/AGTC-Announces-First-Reported-Improvements-in-Visual-Sensitivity-for-Achromatopsia-ACHM-patients-from-its-Ongoing-Clinical-Trials.html

Blocks >= 5000



date time last bid ask volume

09/15/20 16:03:35 4.99 4.80 5.25 17,900
09/15/20 16:00:00 4.99 4.99 5.01 12,900
09/15/20 15:55:31 4.96 4.95 4.97 20,000
09/14/20 16:06:20 4.38 4.35 4.55 276,800
09/14/20 16:00:00 4.38 4.37 4.38 8,700
09/14/20 11:38:17 4.455 4.45 4.46 5,000
09/14/20 10:10:30 4.51 4.53 4.54 8,000
09/14/20 09:30:01 4.55 4.55 4.85 10,400
09/11/20 16:00:00 4.55 4.56 4.57 5,700
09/11/20 15:32:33 4.572 4.57 4.58 5,000
09/11/20 12:53:33 4.54 4.57 4.58 9,600
09/10/20 12:17:27 5.10 5.05 5.07 18,100
09/10/20 10:51:45 5.21 5.19 5.22 10,000
09/10/20 10:30:23 5.20 5.16 5.20 7,500
09/10/20 09:37:53 5.40 5.26 5.32 8,000
09/10/20 09:37:53 5.40 5.26 5.32 6,200
09/10/20 09:32:06 5.33 5.21 5.28 15,300
09/10/20 09:30:01 5.26 5.25 5.38 7,900
09/09/20 16:00:00 5.26 5.33 5.34 20,400
09/09/20 12:31:00 5.16 5.16 5.17 7,500
09/09/20 12:30:42 5.16 5.16 5.17 7,800
09/09/20 12:30:33 5.16 5.16 5.17 8,300
09/09/20 12:30:33 5.16 5.16 5.17 8,900
09/09/20 10:06:05 5.40 5.40 5.41 7,500
09/09/20 10:06:05 5.40 5.40 5.41 26,300
09/09/20 09:39:13 5.6918 5.63 5.72 5,000
09/09/20 09:35:11 5.61 5.62 5.75 10,900
09/09/20 09:30:01 5.98 6.15 6.20 16,300
09/09/20 08:00:01 6.31 6.10 6.15 5,000
09/08/20 16:00:00 6.13 6.13 6.16 8,000
09/08/20 15:57:02 6.23 6.22 6.23 5,124
09/08/20 15:35:55 6.27 6.20 6.22 6,900
09/08/20 15:16:49 6.13 6.07 6.11 8,700
09/08/20 12:10:09 6.05 6.05 6.08 25,000
09/08/20 11:25:58 5.995 5.99 6.00 5,800
09/08/20 09:32:44 5.69 5.69 5.76 8,000
09/04/20 16:00:00 5.86 5.85 5.86 9,900
09/04/20 15:01:06 5.78 5.76 5.80 7,500
09/04/20 15:01:06 5.78 5.76 5.80 7,500
09/04/20 15:01:06 5.78 5.76 5.80 7,500
09/04/20 14:08:45 5.67 5.63 5.71 28,000
09/04/20 10:28:12 5.4401 5.44 5.47 5,900
09/04/20 09:30:01 5.72 5.68 5.82 6,000
09/03/20 16:00:01 5.82 5.82 5.83 19,000
09/03/20 15:43:48 5.95 5.95 5.96 7,600
09/03/20 15:21:16 6.00 5.98 6.02 25,000
09/03/20 15:14:22 6.115 6.11 6.15 7,900
09/03/20 14:27:58 6.175 6.16 6.19 5,000
09/03/20 14:23:16 6.27 6.33 6.38 5,300
09/03/20 14:05:21 6.31 6.39 6.42 5,700
09/03/20 14:04:08 6.40 6.38 6.40 7,000
09/03/20 14:01:12 6.3501 6.35 6.38 6,100
09/03/20 13:54:24 6.44 6.43 6.44 6,000
09/03/20 13:49:45 6.2535 6.22 6.27 5,000
09/03/20 13:16:42 6.40 6.29 6.33 5,500
09/03/20 13:13:35 6.18 6.09 6.13 6,500
09/03/20 12:45:41 6.02 6.00 6.02 13,300
09/03/20 12:30:38 6.10 6.03 6.08 7,200
09/03/20 12:17:37 5.9901 6.02 6.03 5,200
09/03/20 12:16:56 6.05 5.98 6.00 5,200
09/03/20 11:15:56 5.68 5.68 5.70 12,400
09/03/20 10:29:32 5.80 5.73 5.76 5,700
09/03/20 09:30:01 5.66 5.57 5.67 15,200
09/02/20 16:00:00 5.15 5.15 5.16 6,600
09/02/20 09:30:00 5.07 4.95 5.20 6,200
09/01/20 16:00:00 5.14 5.12 5.14 5,100
09/01/20 12:13:27 5.13 5.13 5.16 7,000
08/31/20 16:00:41 5.141 5.11 5.18 5,100
08/31/20 16:00:00 5.14 5.11 5.17 8,500
08/31/20 16:00:00 5.17 5.14 5.16 9,110
08/31/20 15:53:21 5.12 5.18 5.19 8,100
08/28/20 16:00:00 5.17 5.16 5.17 5,500
08/26/20 16:00:00 5.20 5.18 5.20 7,200
08/25/20 16:00:00 5.335 5.33 5.34 9,200
08/24/20 16:00:00 5.15 5.14 5.17 5,600
08/21/20 16:00:00 5.53 5.52 5.53 8,300
08/21/20 09:30:00 5.52 5.42 5.52 7,200
08/20/20 15:11:31 5.5738 5.57 5.59 5,000
08/20/20 10:14:15 5.45 5.44 5.46 99,900
08/17/20 16:18:48 5.87 5.74 6.00 964,800
08/17/20 16:00:00 5.87 5.84 5.87 12,900
08/14/20 15:30:08 5.67 5.70 5.73 6,300
08/14/20 14:11:47 5.80 5.79 5.80 5,200
08/14/20 14:11:47 5.80 5.79 5.80 5,600
08/13/20 16:00:00 5.60 5.59 5.60 6,600
08/13/20 09:30:00 5.70 5.60 6.00 5,100

Historic short interest:

You can go to this link to check short interest in a stock:
http://nasdaqtrader.com/Trader.aspx?id=ShortInterest

Publication schedule is here:
http://nasdaqtrader.com/Trader.aspx?id=ShortIntPubSch


Settlement Date Short Interest Percent Change Average Daily Share Volume Days to Cover

08/31/2020 1,352,364 (46.00) 209,432 6.46
08/14/2020 2,504,600 (9.29) 166,062 15.08
07/31/2020 2,761,023 (0.61) 255,459 10.81
07/31/2020 2,761,023 (0.61) 255,459 10.81
07/15/2020 2,777,843 (5.81) 403,619 6.88
06/30/2020 2,949,163 59.59 716,045 4.12
06/15/2020 1,847,970 99.50 397,013 4.65
05/29/2020 926,297 5.61 289,933 3.19
05/15/2020 877,070 9.76 236,255 3.71
04/30/2020 799,063 (8.96) 135,467 5.90
04/15/2020 877,680 (12.83) 143,024 6.14
03/31/2020 1,006,883 5.42 250,751 4.02
03/13/2020 955,112 (16.61) 300,515 3.18
02/28/2020 1,145,325 7.01 751,785 1.52
02/14/2020 1,070,281 28.58 806,121 1.33
01/31/2020 832,397 57.73 917,717 1.00
01/15/2020 527,735 234.28 5,174,693 1.00
12/31/2019 157,871 119.92 505,792 1.00
12/13/2019 71,787 (21.73) 105,890 1.00
11/29/2019 91,722 24.39 77,524 1.18
11/15/2019 73,736 17.19 84,635 1.00
10/31/2019 62,920 45.97 63,752 1.00
10/15/2019 43,105 (38.67) 104,053 1.00
09/30/2019 70,286 154.52 404,055 1.00
09/13/2019 27,615 (47.89) 132,094 1.00
08/30/2019 52,996 11.13 102,535 1.00
08/15/2019 47,689 44.57 117,027 1.00

JUST IN: $AGTC AGTC to Participate at Upcoming Virtual Investor Conferences

GAINESVILLE, Fla., and CAMBRIDGE, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company focused on developing adeno-associated virus (AAV) based gene therapies for the treatment of rare inherited diseases, today announced ...

Find out more AGTC - AGTC to Participate at Upcoming Virtual Investor Conferences

Historic short interest:

You can go to this link to check short interest in a stock:
http://nasdaqtrader.com/Trader.aspx?id=ShortInterest

Publication schedule is here:
http://nasdaqtrader.com/Trader.aspx?id=ShortIntPubSch


Settlement Date Short Interest Percent Change Average Daily Share Volume Days to Cover


07/31/2020 2,761,023 (0.61) 255,459 10.81
07/15/2020 2,777,843 (5.81) 403,619 6.88
06/30/2020 2,949,163 59.59 716,045 4.12
06/15/2020 1,847,970 99.50 397,013 4.65
05/29/2020 926,297 5.61 289,933 3.19
05/15/2020 877,070 9.76 236,255 3.71
04/30/2020 799,063 (8.96) 135,467 5.90
04/15/2020 877,680 (12.83) 143,024 6.14
03/31/2020 1,006,883 5.42 250,751 4.02
03/13/2020 955,112 (16.61) 300,515 3.18
02/28/2020 1,145,325 7.01 751,785 1.52
02/14/2020 1,070,281 28.58 806,121 1.33
01/31/2020 832,397 57.73 917,717 1.00
01/15/2020 527,735 234.28 5,174,693 1.00
12/31/2019 157,871 119.92 505,792 1.00
12/13/2019 71,787 (21.73) 105,890 1.00
11/29/2019 91,722 24.39 77,524 1.18
11/15/2019 73,736 17.19 84,635 1.00
10/31/2019 62,920 45.97 63,752 1.00
10/15/2019 43,105 (38.67) 104,053 1.00
09/30/2019 70,286 154.52 404,055 1.00
09/13/2019 27,615 (47.89) 132,094 1.00
08/30/2019 52,996 11.13 102,535 1.00
08/15/2019 47,689 44.57 117,027 1.00

Millenium management is Integrated Core Strategies..

From Google..

sc13dza - SEC.govwww.sec.gov › Archives › edgar › data
Millennium Management is the general partner of Integrated Holdings Group LP, a Delaware limited partnership (“Integrated Holding Group”), which is the managing member and 100% shareholder of Integrated Core Strategies (US) LLC, and consequently may be deemed to have shared voting control and investment discretion over ...

Interesting little dip today, up from here????

Well, the gap is definitely filled, anyone have a timeline for this one?

SARS-CoV-2 genes matter

Nice summary in this article:


6. Conclusion
In conclusion, the occurrence and development of SARS-CoV-2 depend on the interaction between the virus and the individual’s immune system. Viral factors include virus type, mutation, viral load, viral titer, and viability of the virus in vitro. The individual’s immune system factors include genetics (such as HLA genes), age, gender, nutritional status, neuroendocrine-immune regulation, and physical status. These factors all contribute to whether an individual is infected with the virus, the duration and severity of the disease, and the reinfection. In the early stages of the epidemic, accurate diagnosis helps control the spread of the disease. It is imperative to develop new, safe, accurate, fast and simple new technologies for detecting SARS-CoV-2. Of course, physicians will intentionally intervene in the two factors to make them develop into a direction beneficial to human health, which can help patients recover as soon as possible. However, it must not be considered that medical intervention can achieve a 100% curative effect.


https://www.sciencedirect.com/science/article/pii/S2095177920302045

Security AGTC / Applied Genetic Technologies Corp (03820J100)
President and CEO Washer Susan B.
ISIN US03820J1007
Industry Biological Products, Except Diagnostic Substances (Biotech)
Institutional Owners 95
Institutional Shares 8,355,406 - 45.86%
Common Shares Outstanding 18,218,402 shares (as of 2019-09-30)
Institutional Value $ 37,767 USD



2020-02-14 13G/A INTERWEST PARTNERS VIII LP 1,484,167 8.20
2020-02-14 13D/A GLAXOSMITHKLINE PLC 0 0.00
2020-02-12 13G/A DIMENSIONAL FUND ADVISORS LP 979,723 5.38
2020-02-12 13G Renaissance Technologies LLC 1,214,340 6.67
2020-02-11 13G/A BIOGEN INC. 0 0.00
2020-01-27 13G/A Stichting Aescap 2.0 1,805,761 9.90




https://fintel.io/so/us/agtc

Gap filled???

X-linked juvenile retinoschisis: Clinical diagnosis, genetic analysis, and molecular mechanisms

Robert S. Molday a,*, Ulrich Kellner b
, Bernhard H.F. Weber c
aDepartment of Biochemistry and Molecular Biology, Centre of Macular Research, University of British Columbia, 2350 Health Sciences Mall, Vancouver, B.C. V6T 1Z3, Canada b Center of Rare Retinal Disease, AugenZentrum Siegburg, MVZ ADTC Siegburg GmbH, Europaplatz 3, D-53721 Siegburg, Germany
cUniversity of Regensburg, Institute of Human Genetics, Franz-Josef-Strauss-Allee 11, D-97053 Regensburg, Germany

X-linked juvenile retinoschisis (XLRS, MIM 312700) is a common early onset macular degeneration in
males characterized by mild to severe loss in visual acuity, splitting of retinal layers, and a reduction in
the b-wave of the electroretinogram (ERG). The RS1 gene (MIM 300839) associated with the disease
encodes retinoschisin, a 224 amino acid protein containing a discoidin domain as the major structural
unit, an N-terminal cleavable signal sequence, and regions responsible for subunit oligomerization.
Retinoschisin is secreted from retinal cells as a disulphide-linked homo-octameric complex which binds
to the surface of photoreceptors and bipolar cells to help maintain the integrity of the retina. Over 190
disease-causing mutations in the RS1 gene are known with most mutations occurring as
non-synonymous changes in the discoidin domain. Cell expression studies have shown that diseaseassociated missense mutations in the discoidin domain cause severe protein misfolding and retention
in the endoplasmic reticulum, mutations in the signal sequence result in aberrant protein synthesis, and
mutations in regions flanking the discoidin domain cause defective disulphide-linked subunit assembly,
all of which produce a non-functional protein. Knockout mice deficient in retinoschisin have been
generated and shown to display most of the characteristic features found in XLRS patients. Recombinant
adeno-associated virus (rAAV) mediated delivery of the normal RS1 gene to the retina of young knockout
mice result in long-term retinoschisin expression and rescue of retinal structure and function providing
a ‘proof of concept’ that gene therapy may be an effective treatment for XLRS.
2012 Elsevier Ltd. All rights reserved



https://agtc.com/wp-content/uploads/2018/04/Molday-XLRS-review-Prog-Ret-Eye-Res-2012.pdf

Gene therapy is the process of modifying a patient’s cells by adding a functional copy of the mutated gene which is causing the patient disease.The new functional copy allows a patient’s own body to produce proteins to treat or prevent genetic conditions. A single treatment can provide long lasting benefits, potentially leading to a better quality of life.

Genetic therapies are complex, with interdependent components that must work in harmony.Fifteen years of gene therapy experience allows us at AGTC to design and construct all critical gene therapy elements and bring them together to develop successful treatments for patients.


AGTC is developing novel formulations for gene therapy. These formulations have shown promise in their ability to increase the concentration and stability of the gene therapy while reducing unwanted effects for the patient. Our proprietary formulation allows us to reach therapeutic doses at lower volumes which enhances the ability of the therapy to benefit patients.

Manufacturing & Characterization
AAV vectors have broad potential to treat a variety of genetic conditions. Our proprietary manufacturing system allows us to handle large volumes, reduce cost, and increase potency and purity of gene therapy treatments. We combine the consistent high yields from our manufacturing system with advanced characterization methods to accelerate the development of gene therapies into human clinical trials. This production and characterization system has been positively reviewed by the U.S. Food & Drug Administration (FDA) and European Medicines Agency (EMA) for use in human clinical trials and has been successfully transferred to multiple vendors and partners.

Vector Administration
AGTC currently employs two different methods for delivery of our ophthalmic products: intravitreal and subretinal. These delivery techniques have been carefully selected for each individual disease state in order to optimize patient outcomes, vector uptake and procedural logistics.

Intravitreal administration involves delivery of the AAV vector into the vitreous cavity, the gel-like substance within the eye. This procedure is performed in an outpatient setting and is routinely performed for delivery of other approved ophthalmic products.

Subretinal administration is a minimally invasive surgical procedure which involves delivery of the AAV vector underneath the retina. Although this delivery method is a more direct way to introduce the vector to the targeted cells, it requires general anesthesia and a refined surgical technique aimed at maximizing potential benefit while minimizing risks.

AGTC is also in the process of identifying novel capsids that would allow for treatment of additional diseases through intravitreal delivery, without the need for subretinal surgery. This will allow more clinicians to administer AGTC products with the goal of treating larger patient populations.






https://agtc.com/science/

February 19, 2020 at 7:00 AM ESTPDF Version

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 19, 2020 (GLOBE NEWSWIRE) — Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it has completed enrollment in the two highest dose groups of its Phase 1/2 clinical trial evaluating the safety and efficacy of sub-retinal injection of AGTC-501 for the treatment of X-linked retinitis pigmentosa (XLRP) caused by mutations in the RPGR gene. The patients in these additional groups received a higher or highest dose of AGTC’s XLRP candidate.

“We expect that the information that will be obtained from the two additional dose groups will help to reinforce the data generated to date and previously reported in September 2019 and January 2020,” said Sue Washer, president and CEO of AGTC. “We plan to report interim data from these two new dose groups and to report top-line 12-month data for the first four dose groups in the second half of 2020 and intend to initiate a pivotal trial by the end of the year. Combined with the ongoing progress in our two achromatopsia clinical studies, we expect to have multiple data read-outs in 2020 that will build on the momentum we created in January.”

AGTC most recently reported data from the ongoing XLRP Phase 1/2 clinical trial in January 2020. Results at the six-month time point in patients dosed centrally were indicative of durable and meaningful improvements in central visual sensitivity, encouraging improvements in Best Corrected Visual Acuity and a favorable safety profile.


https://agtc.com/agtc-announces-completion-of-enrollment-in-the-two-highest-dose-groups-of-its-ongoing-phase-1-2-clinical-trial-in-patients-with-x-linked-retinitis-pigmentosa/

* * $AGTC Video Chart 02-18-2020 * *

Link to Video - click here to watch the technical chart video

* * $AGTC Video Chart 01-22-2020 * *

Link to Video - click here to watch the technical chart video

* * $AGTC Video Chart 01-10-2020 * *

Link to Video - click here to watch the technical chart video

What a beastly beast of bio madness.

$AGTC normally don’t go long but I am here.

* * $AGTC Video Chart 01-09-2020 * *

Link to Video - click here to watch the technical chart video

Yup, should be at least some pull back to fill that gap up today even if it keeps going after that.

+$$$ AGTC

Winner winner chicken dinner

Valuation way to high here, correction coming

$AGTC holding long here

$AGTC nice gains here today

It's on one.

foc me!!!

all out...bios always get news at bottom...boom!!!

$AGTC Weeeeeeeeeeee!!!

look now chump

$AGTC looking good